The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents

International Journal of Dermatology
Tulin ErgunSait Karakurt

Abstract

Tumor necrosis factor-alpha (TNF-α) antagonist treatment is associated with 1.6 to 27 times higher risk of tuberculosis (TB). To find TB incidence of psoriasis patients treated with TNF- α antagonists and define risk factors related with this condition in a country with moderately high risk of TB. Three hundred seventy psoriasis patients treated by anti-TNF agents in four referral centers were included. The data on the characteristics of the patients, TB history, tuberculosis skin test results, anti-TNF agent type and exposure time, localization of TB, and isoniazide prophylaxis state were analyzed. Four patients (1.08%) developed TB, three pulmonary and one gastrointestinal, 2-23 months after initiating anti-TNF agents. Other than the patient with gastrointestinal TB, who was using methotrexate and corticosteroid concomitantly, none had contributing risk factors for TB. Two patients developed pulmonary TB in spite of chemoprophylaxis. Three patients with pulmonary TB completely recovered following antiTB treatment whereas patients with gastroinrestinal TB developed renal failure. The major limitation of the study is the lack of a diseased control group, which enables us to compare the risk of psoriatics with that of patients h...Continue Reading

References

Oct 13, 2001·The New England Journal of Medicine·J KeaneM M Braun
Feb 12, 2004·Arthritis and Rheumatism·Frederick WolfeKathy Urbansky
Mar 1, 2006·Expert Opinion on Drug Safety·Eric J Forget, Dick Menzies
Aug 13, 2008·Journal of the American Academy of Dermatology·Claudia HernandezJune K Robinson
Aug 19, 2008·Autoimmunity Reviews·Ajit Lalvani, Kerry A Millington
Dec 5, 2008·Clinical Rheumatology·Osman ElbekOner Dikensoy
Jun 18, 2009·The American Journal of Gastroenterology·Josh MarehbianWilliam J Sandborn
May 14, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·A I Sánchez-Moya, E Dauden
Sep 13, 2011·Médecine et maladies infectieuses·N MrozekH Laurichesse

❮ Previous
Next ❯

Citations

Jun 4, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·E GuinardUNKNOWN French Psoriasis Research Group
Nov 7, 2017·International Journal of Molecular Sciences·Kirsten Rønholt, Lars Iversen
Mar 29, 2019·American Journal of Clinical Dermatology·Igor SnastLev Pavlovsky
Feb 6, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·E FowlerJ J Wu
Sep 5, 2017·Clinical & Translational Immunology·Michael KammüllerTodd Fox
Jun 20, 2019·Dermatology Research and Practice·Asmah JoharKwee Eng Tey
Dec 4, 2020·PloS One·Vanessa Lucília Silveira de MedeirosVera Magalhães
Oct 31, 2019·Case Reports in Dermatology·Simone RiberoPaolo Dapavo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
L SichletidisD Patakas
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Isaac I BogochDavid C Hooper
Biologics : Targets & Therapy
Khaldoon M AlawnehKhaldoun Bashaireh
© 2022 Meta ULC. All rights reserved